Usher Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Usher Syndrome Market Outlook

Thelansis’s “Usher Syndrome Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Usher Syndrome treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Usher Syndrome Overview

Usher syndrome is a group of inherited disorders characterized by dual sensory impairment of the auditory and visual systems. It is the most common cause of combined sight and hearing loss, accounting for more than half of deaf-blindness cases. Nine causative genes have been identified and confirmed responsible for the syndrome when mutated, including MYO7A, USH1C, CDH23, PCDH15, and USH1G for Usher type 1; USH2A, ADGRV1, and WHRN for Usher type 2; and CLRN1 for Usher type 3. Usher syndrome is clinically and genetically heterogeneous and is divided into three distinct clinical subtypes: Usher 1, Usher 2, and Usher 3. Usher 1 is the most severe subtype, in which patients exhibit severe to profound bilateral congenital sensorineural hearing loss, most frequently non-progressive, with vestibular areflexia. It accounts for approximately 25-44% of all Usher syndrome cases. Usher 2 represents over half of all cases. Sensorineural hearing loss is typically described as sloping, mild to moderate in the low frequencies and severe to profound in the high frequencies. Infants are usually detected through the newborn hearing screen; however, if unavailable, detection can be overlooked till the end of the first decade of life. Usher 3 is rare in most populations, accounting for approximately 2-4% of all cases. The audiovestibular features are the most variable of the Usher subtypes. Hearing loss is the post-lingual onset and is usually detected in the first decade of life, although onset can be delayed until adulthood. It is typical of a progressive nature, with audiograms showing high frequencies more affected or a U-shaped configuration.

• The Usher syndrome is the most common cause of deaf–blindness worldwide, with a prevalence of between 4 and 17 in 100000 in the USA.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: